S. Nag, C. Deshmukh, M. Jain, P. Reddy, N. Reddy, N. Maharaj, R. Desai, V. Natarajan, K. Gaurav
{"title":"一项前瞻性、单臂、多中心、上市后研究(IV 期),评估 Dr. Reddy's 曲妥珠单抗 (DRL_TZ) 在 HER2 阳性晚期乳腺癌患者中的安全性和免疫原性","authors":"S. Nag, C. Deshmukh, M. Jain, P. Reddy, N. Reddy, N. Maharaj, R. Desai, V. Natarajan, K. Gaurav","doi":"10.1016/j.ejca.2024.113709","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":505596,"journal":{"name":"European Journal of Cancer","volume":"88 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Prospective, Single arm, Multicentre, Post-marketing Study (Phase IV) to evaluate safety and immunogenicity of Dr. Reddy’s Trastuzumab (DRL_TZ) in Patients with HER2-Positive Advanced Breast Cancer\",\"authors\":\"S. Nag, C. Deshmukh, M. Jain, P. Reddy, N. Reddy, N. Maharaj, R. Desai, V. Natarajan, K. Gaurav\",\"doi\":\"10.1016/j.ejca.2024.113709\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":505596,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"88 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejca.2024.113709\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ejca.2024.113709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Prospective, Single arm, Multicentre, Post-marketing Study (Phase IV) to evaluate safety and immunogenicity of Dr. Reddy’s Trastuzumab (DRL_TZ) in Patients with HER2-Positive Advanced Breast Cancer